Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
-0.06 (-0.84%)
Mar 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.82 - 7.20
52 week 3.05 - 13.26
Open 7.12
Vol / Avg. 0.00/498,119.00
Mkt cap 276.91M
P/E     -
Div/yield     -
EPS -0.43
Shares 38.66M
Beta 1.26
Inst. own 57%
May 21, 2015
Cytokinetics Inc Annual Shareholders Meeting (Estimated) - 3:00PM EDT - Add to calendar
May 4, 2015
Q1 2015 Cytokinetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 9, 2015
Cytokinetics Inc at ROTH Conference
Mar 3, 2015
Cytokinetics Inc at Cowen Health Care Conference
Feb 12, 2015
Q4 2014 Cytokinetics Inc Earnings Call - Webcast
Feb 12, 2015
Q4 2014 Cytokinetics Inc Earnings Release
Feb 9, 2015
Cytokinetics Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 5, 2015
Cytokinetics Inc and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 38.80% -31.20%
Operating margin 38.70% -31.43%
EBITD margin - -30.39%
Return on average assets 30.76% -13.55%
Return on average equity 40.88% -19.99%
Employees 92 -
CDP Score - -


280 E Grand Ave
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cytokinetics, Incorporated is a clinical stage biopharmaceutical company. The Company is focussed on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company�s lead drug candidate from its skeletal muscle contractility program, tirasemtiv (formerly known as CK-2017357), is a fast skeletal muscle troponin activator. Cytokinetics holds the rights to tirasemtiv and is independently developing this drug candidate for the potential treatment of Amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The Company is conducting a Phase II clinical trial program for tirasemtiv, including an ongoing Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).

Officers and directors

L.Patrick Patrick Gage Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Sharon A. Barbari Chief Financial Officer, Executive Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Bonnie A. Charpentier Ph.D. Senior Vice President - Regulatory Affairs and Compliance
Age: 60
Bio & Compensation  - Reuters
Fady I. Malik M.D., Ph.D. Senior Vice President - Research and Early Development
Age: 49
Bio & Compensation  - Reuters
Andrew A. Wolff M.D. Senior Vice President - Clinical Research and Development, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Santo J. Costa Independent Director
Age: 68
Bio & Compensation  - Reuters
Denise M. Gilbert Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
John T. Henderson M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters